Diabetic Retinopathy and Diabetic Macular Edema

Cohen, Steven R.; Gardner, Thomas W.

doi:10.1159/000438970

Cited by 112 publications

(82 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite their distinct etiologies, both conditions are characterized by pathological changes to the ocular vasculature, which in turn has driven the search for and development of anti-angiogenic therapeutics. [1][2][3] In nvAMD the blood vessels of the choroid typically penetrate Bruch's membrane and the retinal pigment epithelium, from where they may anastomose with the retinal capillary network to create a disorganized and dysfunctional vascular tangle. The edema that typically accompanies these changes causes swelling and often irreparable damage to the macula.…”

Section: Introductionmentioning

confidence: 99%

A Humanized Antibody against LRG1 that Inhibits Angiogenesis and Reduces Retinal Vascular Leakage

Kallenberg

Tripathi

Javaid

et al. 2020

Preprint

View full text Add to dashboard Cite

Pathological angiogenesis contributes to morbidity in a number of diseases including cancer, diabetic retinopathy and the neovascular form of age-related macular degeneration, leading to significant efforts to develop effective anti-angiogenic therapeutics for these conditions. The field is dominated by inhibitors of vascular endothelial growth factor (VEGF), yet angiogenesis can also be driven and modified by other factors. We have previously demonstrated that leucine-rich alpha-2-glycoprotein 1 (LRG1) contributes to abnormal vessel growth by activating a TGFß switch. Here we report the development and characterisation of a function-blocking fully humanised IgG4 and its Fab fragment, that bind to LRG1 with high affinity and specificity and inhibit vascular leakage in the mouse model of laser-induced choroidal neovascularisation. In summary, we have developed a therapeutic antibody that targets a VEGF-independent signalling axis, which may be effective in a number of conditions either as monotherapy or in combination with other vascular targeted therapies.

show abstract

Section: Introductionmentioning

confidence: 99%

A Humanized Antibody against LRG1 that Inhibits Angiogenesis and Reduces Retinal Vascular Leakage

Kallenberg

Tripathi

Javaid

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Before any clinical signs of vascular damage, neuronal components of the retina have been found to be compromised with retinal function deficit, suggesting neurodegeneration might be an initiating factor leading to vascular damage in DR [3, 4]. Cellular, molecular and biochemical analyses of diabetic retina revealed that neurovascular damage is caused by a number of mechanisms including oxidative stress, apoptosis, neurodegeneration and inflammation that lead to DR [5, 6]. …”

Section: Introductionmentioning

confidence: 99%

Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-( 1-12) Axis in the Pathogenesis of Diabetic Retinopathy

Ola

Alhomida

Ferrario

et al. 2017

CMC

View full text Add to dashboard Cite

Diabetic retinopathy (DR) is a major diabetes complication and the leading cause for vision loss and blindness in the adult human population. Diabetes, being an endocrinological disorder dysregulates a number of hormonal systems including the renin angiotensin system (RAS), which thereby may damage both vascular and neuronal cells in the retina. Angiotensin II (Ang II), an active component of the RAS is increased in diabetic retina, and may play a significant role in neurovascular damage leading to the progression of DR. In this review article, we highlight the role of Ang II in the pathogenesis of retinal damage in diabetes and discuss a newly identified mechanism involving tissue chymase and angiotensin-(1-12) [Ang-(1-12)] pathways. We also discuss the therapeutic effects of potential RAS inhibitors targeting blockade of cellular Ang II formation to prevent/protect the retinal damage. Thus, a better understanding of Ang II formation pathways in the diabetic retina will elucidate early molecular mechanism of vision loss. These concepts may provide a novel strategy for preventing and/or treating diabetic retinopathy, a leading cause of blindness worldwide.

show abstract

“…Revista Digital Universitaria en sus etapas iniciales y no afecta la visión hasta etapas muy avanzadas. Esto hace que, con frecuencia, el diagnóstico, que se basa en la detección de anomalías vasculares por inspección visual, sea tardío y que, al momento del diagnóstico, en 10% de los casos se detecten complicaciones serias, como hemorragia vítrea, desprendimiento de retina traccional o edema macular (Cohen y Gardner, 2016). Por lo tanto, es necesario establecer criterios de valoración temprana, para detectar la rd, mediante puntos de control funcional tempranos (ver figura 3).…”

Section: Sobre Los Criterios De Valoración Temprana De La Función Visunclassified

Pérdida de visión por diabetes: detección y tratamiento

Thebault

2019

RDU

View full text Add to dashboard Cite

La retinopatía diabética (rd), enfermedad de la retina comúnmente clasificada como una complicación vascular de la diabetes, es ahora reconocida como una afección que implica tanto a los vasos como a las neuronas (neurovascular). Muchas evidencias apuntan a que esta neuropatía sensorial resulta de la ruptura de la unidad neurovascular. A pesar de ello, las terapias actuales se centran en limitar las anomalías vasculares, incluyendo la formación de vasos sanguíneos irregulares y la hinchazón en la parte central de la retina (conocida como edema macular). Con base en que la ruptura de la unidad neurovascular es un evento temprano en la rd, muchos esfuerzos científicos se centran en encontrar los mecanismos que se vinculan con su ruptura, para lograr el desarrollo de nuevos tratamientos en etapas tempranas. Sin embargo, también hace falta desarrollar y validar nuevos marcadores tempranos de la función visual para reducir la duración de los ensayos clínicos y acelerar la entrega de nuevos tratamientos contra la rd para la población en general. En este trabajo, revisamos qué es la unidad neurovascular retiniana y las alteraciones tempranas que la misma sufre en condiciones de diabetes, y examinamos a detalle la necesidad de generar criterios de valoración temprana de la función visual para los futuros ensayos clínicos que evalúan los nuevos tratamientos para la rd.

show abstract

Diabetic Retinopathy and Diabetic Macular Edema

Cited by 112 publications

References 81 publications

A Humanized Antibody against LRG1 that Inhibits Angiogenesis and Reduces Retinal Vascular Leakage

A Humanized Antibody against LRG1 that Inhibits Angiogenesis and Reduces Retinal Vascular Leakage

Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-( 1-12) Axis in the Pathogenesis of Diabetic Retinopathy

Pérdida de visión por diabetes: detección y tratamiento

Contact Info

Product

Resources

About